country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P11280A

Copy Link Print Information

PRAME peptide (425-433) acetate

Customer Review

Based on 1 Customer Validation

PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.

For research use only. We do not sell to patients.

Purity: 98.16%
Formula: C₄₆H₈₀N₁₂O₁₂·xC₂H₄O₂
Molecular Weight:993.20 (free base)

Storage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

PRAME peptide (425-433) acetate Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Melanocortin Receptor Isoforms :

In Vitro

The average surface density of PRAME peptide (425-433) acetate on HLA-A*02:01-positive solid tumor cell lines is higher than that of other tested PRAME peptides^[1].
PRAME peptide (425-433) acetate (50 µg/mL; 2-4 h) is presented on T2 cells, enabling 77 anti-PRAME pMHC Fabs to bind potently and selectively to T2 cells presenting PRAME peptide (425-433) acetate/HLA-A*02:01, with EC₅₀ values <11 nM^[1].
PRAME peptide (425-433) acetate (50 µg/mL; 2-4 h) is presented on the surface of T2 cells, enabling 37 anti-PRAME pMHC Fab fragments to exhibit TCR-like binding footprints to PRAME peptide (425-433) acetate/HLA-A*02:01^[1].
PRAME peptide (425-433) acetate (72 h) can be targeted and bound by anti-PRAME peptide (425-433) acetate bispecific antibody-Fc TCE HU-08, HU-38, HU-19, and HU-58; it potently and selectively kills PRAME peptide (425-433) acetate-positive NCI-H1755 and SAOS-2 cancer cell lines, without causing off-target killing of PRAME-negative U87MG cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

NCI-H1755 and SAOS-2
Concentration:

50 µg/mL
Incubation Time:

72 h
Result:

Potently and selectively killed PRAME peptide (425-433) (acetate)-positive NCI-H1755 and SAOS-2 cancer cell lines, with EC₅₀ values as low as 0.02 nM, and show no off-target killing of PRAME-negative U87MG cells.

In Vivo

Immunization in rats with PRAME peptide (425-433) acetate (10 μM) combined with PRAME peptide (425-433)/HLA-A*02:01 pMHC induces selective antibodies; these antibodies bind to the target pMHC complex with high affinity and exhibit extremely low off-target binding to irrelevant peptide-pMHC complexes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Appearance Solid
Molecular Weight 993.20 (free base)
Formula C₄₆H₈₀N₁₂O₁₂·xC₂H₄O₂
Color White to light yellow
Sequence

Ser-Leu-Leu-Gln-His-Leu-Ile-Gly-Leu
Sequence Shortening

SLLQHLIGL
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Skrzypczynska K, et al. Development of a PRAME pMHC targeted T cell engager for solid tumor therapy. MAbs. 2025;17(1):2563773. [Content Brief]

[2]. Dasargyri L, et al. 1020P Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A* 02: 01[J]. Annals of Oncology, 2024, 35: S690.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PRAME peptide (425-433) acetate

Peptide Library

All Melanocortin Receptor Isoforms